Statin Use and Survival in Early Breast Cancer According to Different Intrinsic Subtypes

Area of Science:

• Oncology
• Pharmacology
• Epidemiology

Background:

• Statin use is linked to improved survival in breast cancer patients.
• Data on statin use and survival across different intrinsic breast cancer subtypes are lacking.

Purpose of the Study:

• To investigate the association between statin use and survival in early breast cancer patients.
• To analyze survival differences based on intrinsic breast cancer subtypes and statin use.

Main Methods:

• Retrospective population-based cohort study of 7389 female early breast cancer patients in Finland (1995-2013).
• Analysis of prediagnostic and postdiagnostic statin use, dose, and cholesterol levels.
• Assessment of all-cause and breast cancer-specific mortality using statistical analyses (September-November 2023).

Main Results:

• Prediagnostic statin use was not associated with survival.
• Postdiagnostic statin use correlated with lower breast cancer-specific and all-cause mortality.
• Statin use was linked to improved survival in hormone receptor-positive subtypes (luminal A, luminal B HER2-negative, luminal B HER2-positive).

Conclusions:

• Postdiagnostic statin use is associated with improved survival in early breast cancer, especially in hormone receptor-positive subtypes.
• Findings suggest statin therapy may enhance survival for patients with early hormone receptor-positive breast cancer.
• No significant survival benefit was observed with prediagnostic statin use.